Literature DB >> 30649467

Utility of Columbia classification in focal segmental glomerulosclerosis: renal prognosis and treatment response among the pathological variants.

Akihiro Tsuchimoto1, Yuta Matsukuma1, Kenji Ueki1, Shigeru Tanaka2, Kosuke Masutani3, Kaneyasu Nakagawa4, Koji Mitsuiki4, Noriko Uesugi5, Ritsuko Katafuchi6, Kazuhiko Tsuruya1,7, Toshiaki Nakano1, Takanari Kitazono1.   

Abstract

Background: The utility of the Columbia classification (Col-class) for focal segmental glomerulosclerosis (FSGS) has not yet been fully proven.
Methods: We extracted 201 FSGS patients from 10 nephrology centers in Japan and investigated the difference of a composite renal endpoint, defined as doubling of serum creatinine and/or development of end-stage renal disease, in pathological variants. Sensitivity analysis was used to prove the utility of the Col-class to predict renal outcomes. Additionally, the renal protective effects of steroids and/or immunosuppression (steroid/IS) were investigated in patients stratified according to the Col-class.
Results: The patients were classified into the following variants: not otherwise specified [NOS; n = 121 (60.1%)], perihilar [n = 31 (15.4%)], cellular [n = 19 (9.5%)], tip [n = 17 (8.5%)] and collapsing [n = 13 (6.5%)]. No tip variant patients reached the renal endpoint. The renal outcome in the collapsing variant was significantly poorer than that in the NOS [hazard ratio (HR) 3.71; P = 0.005]. In the sensitivity analysis, the area under the receiver operating characteristic curve for the renal endpoint was increased by adding Col-class to a model including common risk factors (P = 0.021). In a subgroup treated without steroid/IS, the outcome in the cellular variant was worse than that in the NOS (HR 5.10; P = 0.040) but the difference was not observed in the subgroup with steroid/IS (HR 0.54; P = 0.539). Conclusions: The Col-class is useful to predict renal prognosis in Japanese patients with FSGS. In addition to good prognosis in the tip variant and poor in the collapsing variant, good clinical course in the cellular variant treated with steroid/IS was suggested.

Entities:  

Year:  2019        PMID: 30649467     DOI: 10.1093/ndt/gfy374

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  Proteomic Analysis Identifies Distinct Glomerular Extracellular Matrix in Collapsing Focal Segmental Glomerulosclerosis.

Authors:  Michael L Merchant; Michelle T Barati; Dawn J Caster; Jessica L Hata; Liliane Hobeika; Susan Coventry; Michael E Brier; Daniel W Wilkey; Ming Li; Ilse M Rood; Jeroen K Deegens; Jack F Wetzels; Christopher P Larsen; Jonathan P Troost; Jeffrey B Hodgin; Laura H Mariani; Matthias Kretzler; Jon B Klein; Kenneth R McLeish
Journal:  J Am Soc Nephrol       Date:  2020-06-19       Impact factor: 10.121

2.  Prediction model for the risk of ESKD in patients with primary FSGS.

Authors:  Yuting Zhu; Wenchao Xu; Cheng Wan; Yiyuan Chen; Chun Zhang
Journal:  Int Urol Nephrol       Date:  2022-07-01       Impact factor: 2.370

3.  Clinical, Pathological, and Genetic Characteristics in Patients with Focal Segmental Glomerulosclerosis.

Authors:  China Nagano; Shigeo Hara; Norishige Yoshikawa; Asami Takeda; Yoshimitsu Gotoh; Riku Hamada; Kentaro Matsuoka; Masaki Yamamoto; Shuichiro Fujinaga; Koji Sakuraya; Koichi Kamei; Yuko Hamasaki; Hideyo Oguchi; Yoshinori Araki; Yayoi Ogawa; Takayuki Okamoto; Shuichi Ito; Seiji Tanaka; Hiroshi Kaito; Yuya Aoto; Shinya Ishiko; Rini Rossanti; Nana Sakakibara; Tomoko Horinouchi; Tomohiko Yamamura; Hiroaki Nagase; Kazumoto Iijima; Kandai Nozu
Journal:  Kidney360       Date:  2022-05-24

Review 4.  Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association.

Authors:  Manuel Alfredo Podestà; Claudio Ponticelli
Journal:  Front Med (Lausanne)       Date:  2020-11-20

5.  Podocyte-specific Crb2 knockout mice develop focal segmental glomerulosclerosis.

Authors:  Akiko Tanoue; Kan Katayama; Yugo Ito; Kensuke Joh; Masaaki Toda; Taro Yasuma; Corina N D'Alessandro-Gabazza; Hiroshi Kawachi; Kunimasa Yan; Masaaki Ito; Esteban C Gabazza; Karl Tryggvason; Kaoru Dohi
Journal:  Sci Rep       Date:  2021-10-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.